No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML
- PMID: 30889374
- DOI: 10.1016/j.ccell.2019.02.013
No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML
Abstract
A report in this issue of Cancer Cell identifies the RNA-binding protein RBM39 as a potential target in spliceosome mutant AML that can be targeted by existing sulfonamide drugs. These results support a proposed clinical trial in patients with myeloid malignancies bearing spliceosome mutations relapsed or refractory to standard therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.Cancer Cell. 2019 Mar 18;35(3):369-384.e7. doi: 10.1016/j.ccell.2019.01.010. Epub 2019 Feb 21. Cancer Cell. 2019. PMID: 30799057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical